NEWSROOM
Press Releases by Agendia
News
Press Releases
Agendia’s MammaPrint and BluePrint Breast Cancer Tests Selected by Unicancer for French Patients
IRVINE, CA, AMSTERDAM, NETHERLANDS – 15 May 2018 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announce that Unicancer, a hospital group entirely devoted to fighting cancer, has selected the Read More
Agendia’s MammaPrint Receives Positive Coverage Decisions from Three Major Private Healthcare Insurers
Decisions from Aetna, Cigna and UnitedHealthcare followed the latest update to the American Society of Clinical Oncology (ASCO) guidelines recommending MammaPrint® Breast Cancer Risk of Recurrence Test for certain breast cancer patients Majority of U.S. Read More
Agendia Announces CE Mark for NGS-Based MammaPrint BluePrint Kit Enhancing Access to Personalized Treatment for Breast Cancer Patients in Europe
IRVINE, CA, AMSTERDAM, NETHERLANDS – 21 March 2018 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announces that its next-generation sequencing (NGS)-based MammaPrint® BluePrint® Breast Cancer Recurrence and Molecular Read More
Agendia and Bluebee Partner to Bring New NGS-Based MammaPrint BluePrint Breast Cancer Kit to Market
IRVINE, CA, AMSTERDAM, and RIJSWIJK, NETHERLANDS – 19 December 2017 – Agendia, Inc, a world leader in personalized medicine and molecular cancer diagnostics, and Bluebee, a company driving global genomic data-driven medicine, have partnered to Read More
Key Studies Presented at the San Antonio Breast Cancer Symposium Demonstrate the Important Role of MammaPrint for Patient Pre-Selection, Cost-Effectiveness and For Younger Patients
Data from the I-SPY 2 trial showed the first long-term survival results for patients pre-selected as MammaPrint high-risk, with 94% of the patients who achieved pathological complete response event-free at three years MammaPrint assessment Read More
Agendia and UZ Leuven Partner to Co-Validate MammaPrint BluePrint Breast Cancer Risk of Recurrence and Molecular Subtyping Kit Ahead of European Launch
IRVINE, CA, AMSTERDAM, NETHERLANDS – 7 December 2017 – Agendia, a world leader in personalized medicine and molecular cancer diagnostics, and University Hospitals Leuven (UZ Leuven) in Belgium have partnered to co-validate Agendia’s new in Read More
Agendia Collaborates with Prestigious Cancer Center, Institut Curie, for MammaPrint BluePrint Breast Cancer Kit Co-Validation Study
Institut Curie is one of an increasing number of major European cancer centers to become a co-validation partner for the new NGS-based MammaPrint BluePrint Kit IRVINE, CA, AMSTERDAM, and PARIS – 5 December 2017 – Read More
